**Core tip:** The expression of a bile acid receptor TGR5 at moderate to strong intensity was significantly higher in high-grade dysplasia and esophageal adenocarcinoma (EA) cases than in BE or in low-grade dysplasia, suggesting that TGR5 may play an important role in the progression from Barrett's esophagus to high-grade dysplasia and EA. TGR5 might be a potential marker for this progression. TGR5 staining intensity was not associated with the clinical stage, the pathological stage and the status of lymph node metastasis, indicating that TGR5 may not be a marker for the prognosis of EA.

INTRODUCTION
============

Esophageal adenocarcinoma (EA) is a deadly cancer with an increasing incidence\[[@B1]-[@B3]\]. It has a poor prognosis with a median survival of less than one year\[[@B4],[@B5]\] and a five-year survival rate of 12.5%-20%\[[@B6],[@B7]\]. Gastroesophageal reflux disease (GERD) complicated by Barrett's esophagus (BE)\[[@B8]-[@B10]\] is a major risk factor for EA. BE carries nearly a 30-125-fold increased risk for the development of EA, with best estimates of cancer incidence of 0.12%-0.8% per year\[[@B2],[@B10]-[@B14]\]. However, mechanisms of the progression from BE (intestinal metaplasia) to EA are not fully understood.

Bile acids may play an important role in the progression from BE to EA\[[@B15],[@B16]\] since (1) exposure of the lower esophagus to duodenal juice in animal models leads to EA\[[@B17]-[@B19]\]; (2) bile acid causes the production of reactive oxygen species and DNA damage in a non-neoplastic Barrett's cell line BAR-T\[[@B20]\]; (3) bile salts may activate the mitogen-activated protein kinase and NF-κB pathways\[[@B21],[@B22]\] thereby enhancing cell proliferation and preventing cell apoptosis; and (4) Barrett's cells become tumorigenic after long-term exposure to acid and bile acid *in vitro*\[[@B23]\].

A G protein-coupled receptor TGR5 has been shown to mediate bile acids' effects as a cell-surface receptor\[[@B24]\]. The TGR5 receptor is abundantly expressed in human monocytes and macrophages, and participates in the regulation of cell metabolism\[[@B25],[@B26]\]. Primary bile acids (cholic acid, taurocholic acid and glycocholic acid) and secondary bile acids (deoxycholic acid, taurodeoxycholic acid, glycodeoxycholic acid and taurolithocholic acid) have been shown to bind to TGR5 receptors\[[@B24]\]. Primary bile acids are much weaker at inducing cyclic AMP production *via* activation of TGR5 than secondary bile acids. Deoxycholic acid, taurodeoxycholic acid, and glycodeoxycholic acid have similar strengths at inducing cyclic AMP production\[[@B24]\]. TGR5 has been reported to be expressed in human gastric cancers, to promote epithelial-mesenchymal transition in gastric cancer cell lines\[[@B27]\], and to mediate bile acid-induced cholangiocyte proliferation *in vivo* and *in vitro*\[[@B28]\].

We have previously shown that TGR5 receptors are present in EA cells and that TGR5 receptors mediate bile acid-induced increase in cell proliferation\[[@B29]\]. The expression of TGR5 in EA tissues is not well understood. In this study, we examined the bile acid receptor TGR5 expression in squamous mucosa, Barrett's mucosa, dysplasia and EA by immunohistochemistry. We found that TGR5 immunostaining was much stronger in high grade and EA than in BE mucosa or low-grade dysplasia.

MATERIALS AND METHODS
=====================

Patients and specimens
----------------------

Archival cases of BE, low grade dysplasia, high grade dysplasia and EA from 34 patients (18 cases with squamous mucosa, 15 cases with BE, 8 cases with low grade dysplasia, 9 cases with high grade dysplasia and 16 cases with adenocarcinoma) were collected between the years of 2005 and 2013 from the archives of the Department of Pathology at the Rhode Island Hospital (RIH). BE was made based on the histological finding of intestinal metaplasia and the endoscopic finding of column-type mucosa. Patients with previous history of chemoradiation therapy were excluded from the study. Stage was defined according to American Joint Committee on Cancer criteria\[[@B30]\]. This study was approved by the Institutional Review Board at the RIH. All tissue samples were formalin-fixed and paraffin-embedded. The corresponding hematoxylin-eosin slides were reviewed for confirmation of diagnosis and adequacy of material by Dr. Cao W. The detailed clinicopathological features of the study population are given in Table [1](#T1){ref-type="table"}.

###### 

Clinical features of the study group

  **Number**     **34**
  -------------- -----------
  Age (yr)       
  Range          48-91
  Median         65.5
  Sex, *n* (%)   
  Male           28 (82.4)
  Female         6 (17.6)

Immunohistochemistry
--------------------

Immunohistochemistry for TGR5 was performed on 4-μm paraffin sections. Slides were stained with TGR5 antibody (1:1000, Sigma-Aldrich Co., St. Louis, MO) using the DAKO Envision + Dual Link System and the DAKO Liquid 3,3'-diaminobenzidine (DAB+) Substrate Chromagen System (DAKO North America, Inc., Carpinteria, CA). Bile ducts from liver tissue were used as positive controls. Negative controls included replacement of the primary antibody with non-reacting antibodies of the same species. The specificity of TGR5 antibody has been confirmed by Western Blot analysis in our lab\[[@B31]\].

Immunohistochemistry assessment
-------------------------------

Cancers and non-neoplastic mucosa that displayed a strong, well-localized, strong staining pattern for TGR5 were scored as +3, moderately intense staining as +2, and weak staining as +1. The extent of staining (percentage of cells staining) was scored as follows: 1+ 1%-10%, 2+ 11%-50%, 3+ 51%-100%. A combined score of intensity and extent was calculated and categorized as follows: weak staining 1-2, moderate staining 3-4, strong staining 5-6. All sections were scored independently by WC and SM without knowledge of the clinicopathologic features or clinical outcome.

Cell culture
------------

Cell culture was similar to those we described previously\[[@B29],[@B32],[@B33]\]. Briefly, human esophageal squamous HET-1A cells were purchased from ATCC, Manassas, VA in 2011 and cultured in the bronchial epithelial cell medium (BEGM BulletKit, Cambrex, East Rutherford, NJ). Human Barrett's cell line CP-A and Barrett's dysplastic cell line CP-D were bought from ATCC (Manassas, VA) and cultured in Barrett's medium containing keratinocyte medium-2 (Cambrex, Rockland, ME), 1.8 mmol/L CaCl~2~, 5% fetal bovine serum, 400 ng/mL hydrocortisone, 20 ng/ml epidermal growth factor, 0.1 nmol/L cholera toxin, 20 μg/mL adenine, 5 μg/mL insulin, 70 μg/mL bovine pituitary extract, and antibiotics. EA cell line SK-GT-4 was purchased from Sigma and cultured in the Barrett's medium.

Statistical analysis
--------------------

For immunohistochemical data, statistical differences were determined by *χ*^2^ test. For TGR5 mRNA data, data was expressed as mean ± SE. Statistical differences between two groups were determined by Student's *t* test. Differences among multiple groups were tested using analysis of variance and checked for significance using Fisher's protected least significant difference test. *P* values of 0.05 or less were considered statistically significant.

RESULTS
=======

Expression of TGR5 in different cell lines
------------------------------------------

We have previously shown that the levels of TGR5 mRNA and protein expression are significantly increased in Barrett's mucosal tissue, when compared with normal esophageal mucosa. TGR5 mRNA and protein levels are significantly higher in EA tissue than in normal esophageal mucosa or in Barrett's mucosa\[[@B29]\]. Consistent with our previous findings, TGR5 mRNA level was significantly higher in Barrett's cell line CP-A than in squamous cell line HET-1A (Figure [1A](#F1){ref-type="fig"}). Levels of TGR5 mRNA were significantly increased in Barrett's dysplastic cell line CP-D and EA cell line SK-GT-4, when compared with CP-A cells. In addition, TGR5 mRNA was significantly higher in SK-GT-4 cells than in CP-D cells (Figure [1B](#F1){ref-type="fig"}). These data suggest that TGR5 may play an important role in the progression from BE to EA.

![TGR5 mRNA levels in different cell lines. A: TGR5 mRNA level was significantly higher in Barrett's cell line CP-A than in squamous cell line HET-1A; B: Levels of TGR5 mRNA were significantly increased in Barrett's dysplastic cell line CP-D and EA cell line SK-GT-4, when compared with CP-A cells. In addition, TGR5 mRNA was significantly higher in SK-GT-4 cells than in CP-D cells. These data suggest that TGR5 may play an important role in the progression from BE to EA. *n* = 3, *t* test, ^a^*P* \< 0.02; ANOVA, ^b^*P* \< 0.01 *vs* CP-A.](WJG-23-1338-g001){#F1}

Expression of TGR5 in squamous mucosa, BE mucosa, low grade dysplasia and EA
----------------------------------------------------------------------------

We have previously shown that TGR5 antibody is relatively specific since only one band was detectable by using TGR5 antibody\[[@B31]\]. The expression of TGR5 in squamous mucosa, BE mucosa, low-grade dysplasia and EA was further examined by immunohistochemistry. We found that 93.3% Barrett's mucosa showed weak to moderate TGR5 staining, which was significantly higher than squamous mucosa (27.8%) (Figure [2](#F2){ref-type="fig"} and Table [2](#T2){ref-type="table"}). Moderate to strong TGR5 staining was significantly higher in EA cases (100%) than in BE (13.3%, *P* \< 0.001) or in low-grade dysplasia (37.5%, *P* \< 0.01) (Figure [2](#F2){ref-type="fig"} and Table [2](#T2){ref-type="table"}). Similarly, moderate to strong TGR5 staining was significantly higher in high-grade dysplasia cases (88.9%) than in BE (13.3%, *P* \< 0.001) or in low-grade dysplasia (37.5%, *P* \< 0.05) (Figure [2](#F2){ref-type="fig"} and Table [2](#T2){ref-type="table"}). Moderate to strong staining was slightly higher in low-grade dysplasia (37.5%) than in BE mucosa (13.3%), but there is no statistical significance. TGR5 staining had no significant difference between high-grade dysplasia and EA.

###### 

TGR5 expression in squamous mucosa, Barrett's esophagus, low-grade dysplasia, high-grade dysplasia and esophageal adenocarcinoma *n* (%)

                                                   **Negative**   **Weak**   **Moderate**   **Strong**   
  ------------------------------------------------ -------------- ---------- -------------- ------------ ---------------------------------------------
  Squamous mucosa, *n* = 18                        13 (72)        5 (28)     0              0            
  Barrett's esophagus, *n* = 15                    1 (6.7)        12 (80)    2 (13.3)       0            *P* \< 0.001, compared with squamous mucosa
  Low grade dysplasia, *n* = 8                     0              5 (62.5)   2 (25)         1 (12.5)     *P* \> 0.05, compared with BE
  High grade dysplasia, *n* = 9                    1 (11.1)       0          2 (22.2)       6 (66.7)     *P* \< 0.001, compared with BE
  *P* \< 0.05, compared with low grade dysplasia                                                         
  EA, *n* = 16                                     0              0          7 (43.7)       9 (56.3)     *P* \< 0.001, compared with BE
  *P* \< 0.01, compared with low grade dysplasia                                                         

EA: Esophageal adenocarcinoma; BE: Barrett's esophagus.

![Representative images of squamous mucosa, Barrett's esophagus mucosa, low-grade dysplasia, high-grade dysplasia and esophageal adenocarcinoma. Upper panel: Hematoxylin-eosin staining stain, Lower panel: TGR5 immunostaining, magnification × 200. EA: Esophageal adenocarcinoma.](WJG-23-1338-g002){#F2}

Expression of TGR5 in different stages of EA
--------------------------------------------

Next, we compared the expression of TGR5 in different clinical and pathological stages of EA tissues. We found that 100% stage III and IV cases showed moderate to strong staining, which was the same as stage I and II cases (100%; Table [3](#T3){ref-type="table"}), indicating that the degree of TGR5 expression might not be associated with clinical stages. T3 and T4 cancers had 63.6% strong TGR5 staining, which was not different from T1 and T2 cancers (*P* \> 0.05; Table [4](#T4){ref-type="table"}). In addition, TGR5 expression had no significant difference between tumors with and without lymph node metastasis (Table [5](#T5){ref-type="table"}).

###### 

TGR5 expression in different clinical stages of esophageal adenocarcinoma *n* (%)

  **Clinical stage**    **Negative**   **Weak**   **Moderate**   **Strong**   
  --------------------- -------------- ---------- -------------- ------------ -------------
  I and II, *n* = 9     0              0          4 (44.4)       5 (55.6)     
  III and IV, *n* = 7   0              0          3 (42.9)       4 (57.1)     *P* \> 0.05

###### 

TGR5 expression in different pathological stages of esophageal adenocarcinoma *n* (%)

  **Pathological stage**   **Negative**   **Weak**   **Moderate**   **Strong**   
  ------------------------ -------------- ---------- -------------- ------------ -------------
  T1 and T2                0              0          2 (40)         3 (60)       
  T3 and T4                0              0          4 (36.4)       7 (63.6)     *P* \> 0.05

###### 

TGR5 expression in patients with or without lymph node metastasis of esophageal adenocarcinoma *n* (%)

  **Lymph node metastasis**   **Negative**   **Weak**   **Moderate**   **Strong**   
  --------------------------- -------------- ---------- -------------- ------------ -------------
  Positive                    0              0          2 (33.3)       4 (66.7)     *P* \> 0.05
  Negative                    0              0          5 (50)         5 (50)       

DISCUSSION
==========

GERD complicated by BE\[[@B8]-[@B10]\] is a major risk factor for EA. There is a progression from BE, to dysplasia and to EA. The mechanisms of progression from BE to EA are not fully understood. Many genetic and epigenetic alterations, chromosomal gains and losses, and hypermethylation of gene promoters may be involved in this progression\[[@B13],[@B34]\]. Bile acids have also been indicated to be involved in this progression\[[@B15],[@B16]\].

We have previously shown that TGR5 receptors are present in EA cells and that TGR5 mediates bile-acid-induced increase in cell proliferation, suggesting that TGR5 may be important in the development of EA\[[@B29]\]. We have also reported that moderate to strong TGR5 staining is associated with decreased patient survival in all gastric adenocarcinomas, suggesting that TGR5 may be a negative prognostic marker in gastric cancer\[[@B31]\]. The histological expression of TGR5 in EA has not been reported.

In this study, we examined TGR5 mRNA expression in different cell lines and found that Barrett's cells CP-A had significantly higher levels of TGR5 mRNA than squamous cells HET-1A. Moreover, Barrett's dysplastic cells CP-D had significantly higher levels of TGR5 mRNA than CP-A cells. EA cells SK-GT-4 had much higher levels of TGR5 mRNA than CP-A or CP-D. These data suggest that TGR5 may be involved in the progression from BE to EA.

Next, we examined the TGR5 expression in squamous mucosa, Barrett's mucosa, dysplasia and EA. We found that moderate to strong TGR5 staining was significantly higher in high-grade dysplasia and EA cases than in BE or in low-grade dysplasia. Moderate to strong staining was slightly higher in low-grade dysplasia than in BE mucosa, but there is no statistical significance. TGR5 staining had no significant difference between high-grade dysplasia and EA. These data further support our above results that TGR5 may play an important role in the progression from BE to EA. How TGR5 is involved in this progression is not clear. Recently we found that TGR5 mediates bile acid-induced activation of cyclic AMP response element binding protein (CREB) and NADPH oxidase NOX5-S, which produces reactive oxygen species and causes DNA damage\[[@B35]\]. TGR5 is present in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines\[[@B27]\]. It also mediates bile acid-induced cholangiocyte proliferation *in vivo* and *in vitro*\[[@B28]\]. Therefore, we speculate that in Barrett's patients bile acids may activate TGR5 receptors, which activate CREB and NOX5-S. NOX5-S-derived ROS may increase cell proliferation and cause DNA damage, thereby contributing to the progression from BE to EA. TGR5 might be a potential marker for the progression from BE to high-grade dysplasia and EA. In addition, we compared the expression of TGR5 in different clinical stages of EA tissues. We found that 100% stage III and IV cases showed moderate to strong staining, which was the same as stage I and II cases, indicating that the degree of TGR5 expression might not be associated with clinical stages. Moreover, TGR5 expression had no significant difference between tumors with and without lymph node metastasis, indicating that the degree of TGR5 expression may not be related to the status of lymph node metastasis. These data suggest that TGR5 may not be a marker for the prognosis of EA.

In conclusion, TGR5 immunostaining was much stronger in high-grade dysplasia and EA than in BE mucosa or low-grade dysplasia. Its staining intensity was not associated with the clinical stage, pathological stage and the status of lymph node metastasis.
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